ALICIA RODRÍGUEZ GASCÓN-rekin lankidetzan egindako argitalpenak (241)

2024

  1. Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893

  2. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells

    Journal of Drug Delivery Science and Technology, Vol. 99

  3. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach

    Antibiotics, Vol. 13, Núm. 6

  4. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 404-416

  5. Streptococcus pneumoniae eta Haemophilus influenzae bakterio-espezieek eragindako infekzio inbaditzaile eta ez-inbaditzaileak: txertaketaren eraginak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 45, pp. 71-92

  6. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

    BioDrugs, Vol. 38, Núm. 5, pp. 657-680

  7. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628

2023

  1. Absorción de fármacos

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 181-198

  2. Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study

    The Lancet Microbe, Vol. 4, Núm. 12, pp. e994-e1004

  3. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  4. Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  5. Extended infusion of piperacillin/tazobactam: pharmacokinetics in critically ill patients

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  6. Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  7. Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

    Pharmaceutics, Vol. 15, Núm. 7

  8. Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?

    Pharmaceutics, Vol. 15, Núm. 4

  9. SLNs como sistemas de transfección para el desarrollo deterapias CAR-T ex vivo

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  10. Terapia génica

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 137-153

  11. siRNA vectors based on golden lipid nanoparticles for Fabry Disease

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  12. ¿Incrementa la descontaminación digestiva selectiva la resistencia a antibióticos? Comparación entre dos Servicios de Medicina Intensiva de un hospital terciario

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

    Nanomaterials, Vol. 12, Núm. 14